



MAY 2021

KMAP GENERAL BULLETIN 21089

EUA Coverage Change for Bamlanivimab

Effective April 16, 2021, procedure codes M0239 and Q0239 will be discontinued due to the Food and Drug Administration (FDA) revocation of the Emergency Use Authorization (EUA) of Bamlanivimab when administered alone.

Note: The effective date of the policy is April 16, 2021. The implementation of State policy by the KanCare Managed Care Organizations (MCOs) may vary from the date noted in the Kansas Medical Assistance Program (KMAP) bulletins. The **KanCare Open Claims Resolution Log** on the KMAP [Bulletins](#) page documents the MCO system status for policy implementation and any associated reprocessing completion dates, once the policy is implemented.

KMAP

[Kansas Medical Assistance Program](#)

- [Bulletins](#)
- [Manuals](#)
- [Forms](#)

Customer Service

- 1-800-933-6593
- 7:30 a.m. - 5:30 p.m.
Monday - Friday